Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

被引：8
|
作者：
Sonneveld, Pieter
Asselberg-Hacker, Emilie
Zweegman, Sonja
van der Holt, Bronno
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.688.688
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
688
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Comparison of thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant eligible
    R Soutar
    M Steel
    A Donaldson
    C Walbaum
    Annals of Hematology, 2020, 99 : 905 - 906
  • [22] Comparison of thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant eligible
    Soutar, R.
    Steel, M.
    Donaldson, A.
    Walbaum, C.
    ANNALS OF HEMATOLOGY, 2020, 99 (04) : 905 - 906
  • [23] Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial
    Lu, Jin
    Lee, Jae H.
    Huang, Shang-Yi
    Qiu, Lugui
    Lee, Je-Jung
    Liu, Ting
    Yoon, Sung-Soo
    Kim, Kihyun
    Shen, Zhi X.
    Eom, Hyeon S.
    Chen, Wen M.
    Min, Chang K.
    Kim, Hyo J.
    Lee, Jeong O.
    Kwak, Jae Y.
    Yiu, Wai
    Chen, Guang
    Ervin-Haynes, Annette
    Hulin, Cyrille
    Facon, Thierry
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (05) : 743 - 749
  • [24] Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial
    Lu, Jin
    Lee, Jae Hoon
    Huang, Shang-Yi
    Qiu, Lugui
    Lee, Je-Jung
    Liu, Ting
    Yoon, Sung-Soo
    Kim, Kihyun
    Shen, Zhi Xiang
    Eom, HyeonSeok
    Chen, Wenming
    Min, Chang-Ki
    Kim, Hyo Jung
    Lee, Jeong Ok
    Kwak, Jae Yong
    Yiu, Wai
    Chen, Guang
    Haynes, Annette Ervin
    Hulin, Cyrille
    Facon, Thierry
    BLOOD, 2015, 126 (23)
  • [25] A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma
    Biran, Noa
    Vesole, David H.
    Parmar, Harsh
    Phull, Pooja
    Doucette, Kimberly
    Feinman, Rena
    Zenreich, Joshua
    Anand, Palka
    Ivanovski, Kristin
    Pace, Monique
    Biamonte, Lisa
    Campanaro, Martha
    McClendon, Trina
    Limbad, Chandani
    BaboolallAracena, Samanta
    Aleman, Adolfo
    Unawane, Rashmi
    Pendergrass, Elizabeth
    Layton, Marie
    Breeze, Genevieve
    Chappell, Aimee
    Della Pia, Alexandra
    Kumka, Susan
    Siegel, David S.
    BLOOD, 2023, 142
  • [26] Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma
    Elias K. Mai
    Thomas Hielscher
    Uta Bertsch
    Jana Schlenzka
    Hans J. Salwender
    Markus Munder
    Christian Gerecke
    Ulrich Dührsen
    Peter Brossart
    Kai Neben
    Jens Hillengass
    Marc S. Raab
    Maximilian Merz
    Marc-Andrea Baertsch
    Anna Jauch
    Dirk Hose
    Hans Martin
    Hans-Walter Lindemann
    Igor W. Blau
    Christof Scheid
    Katja C. Weisel
    Hartmut Goldschmidt
    Leukemia, 2019, 33 : 258 - 261
  • [27] Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma
    Mai, Elias K.
    Hielscher, Thomas
    Bertsch, Uta
    Schlenzka, Jana
    Salwender, Hans J.
    Munder, Markus
    Gerecke, Christian
    Duehrsen, Ulrich
    Brossart, Peter
    Neben, Kai
    Hillengass, Jens
    Raab, Marc S.
    Merz, Maximilian
    Baertsch, Marc-Andrea
    Jauch, Anna
    Hose, Dirk
    Martin, Hans
    Lindemann, Hans-Walter
    Blau, Igor W.
    Scheid, Christof
    Weisel, Katja C.
    Goldschmidt, Hartmut
    LEUKEMIA, 2019, 33 (01) : 258 - 261
  • [28] Low-dose dexamethasone and thalidomide with higher frequency zoledronic acid (dtZ) for newly diagnosed multiple myeloma
    Teoh, G.
    Tan, D.
    Chuah, C.
    Hwang, W.
    Yiu, R.
    Kuperan, P.
    Tien, S.
    Lee, L.
    Ang, A.
    Kam, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
    O'Donnell, Elizabeth K.
    Mo, Clifton C.
    Nadeem, Omar
    Yee, Andrew J.
    Branagan, Andrew R.
    Laubach, Jacob
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette
    Harrington, Cynthia C.
    Agyemang, Emerentia
    Rosenblatt, Jacalyn
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur
    BLOOD, 2022, 140 : 7282 - 7283
  • [30] A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
    O'Donnell, Elizabeth K.
    Mo, Clifton C.
    Yee, Andrew J.
    Nadeem, Omar
    Branagan, Andrew R.
    Laubach, Jacob
    Rosenblatt, Jacalyn
    Horick, Nora
    Richardson, Paul G.
    Raje, Noopur
    Cirstea, Diana
    BLOOD, 2023, 142
12345